Detailed Coverage

Granules India Posts Strong Q1 FY27 Results

Revenue: ₹1,477 crore (+22% YoY)
PAT: ₹180 crore (+60% YoY)

Reader Takeaway: Margin expansion and debt reduction show strategic progress, but regulatory clearance remains a watch point.

What just happened

Granules India announced its financial results for the first quarter of FY27, showcasing significant year-on-year growth. Revenue climbed 22% to ₹1,477 crore, while Profit After Tax (PAT) surged by 60% to ₹180 crore. EBITDA also saw a healthy increase of 37% to ₹339 crore, with EBITDA margins at 22.9%.

Why this matters

These results highlight the company's successful shift towards higher-value products and improved operational efficiency. The strong PAT growth suggests enhanced profitability, while the significant reduction in net debt and improved operating cash flow demonstrate a healthier balance sheet.

The backstory

Granules India has been strategically focusing on complex generics and its peptide Contract Development and Manufacturing Organization (CDMO) business. This quarter marks a significant achievement with complex generics now representing 50% of finished dosages, up from 39% last year. The peptide CDMO segment experienced over 100% growth.

What changes now

The company's strategic pivot appears to be paying off, with improved margins and profitability. The peptide CDMO platform is being scaled up with a target of $50 million in revenue and over 30% EBITDA margin within three years. Remediation at the Gagillapur facility is nearing completion, with most facilities holding clean inspection reports.

Risks to watch

Key concerns include the pending Establishment Inspection Report (EIR) for one facility in Gagillapur, which is crucial for launching nine pending applications. Product launches tied to ongoing litigation introduce revenue timing uncertainty. Global geopolitical tensions may continue to impact raw material and freight costs.

Peer comparison

(No direct peer comparison was provided in the filing. Granules India's focus on complex generics and peptide CDMO is a differentiator in the Indian pharmaceutical landscape.)

Context metrics (time-bound)

• Revenue (Q1 FY27): ₹1,477 crore (+22% YoY)
• PAT (Q1 FY27): ₹180 crore (+60% YoY)
• EBITDA (Q1 FY27): ₹339 crore (+37% YoY)
• EBITDA Margin (Q1 FY27): 22.9%
• Net Debt (Q1 FY27): ₹1,012 million (down from ₹4,021 million at end of FY26)
• Operating Cash Flow (Q1 FY27): ₹3,874 million

What to track next

Investors will be closely watching the clearance of the Gagillapur facility, the progress of the peptide CDMO business towards its revenue and margin targets, and the company's ability to navigate raw material inflation and litigation risks.